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Abstract 
The melanocortin-1 receptor (MC1R) is a key regulator of mammalian pigmentation. 
Melanism in the grey squirrel is associated with an eight amino acid deletion in the 
MC1RΔ24 variant. We demonstrate that the MC1RΔ24 exhibits a higher basal activity than 
the wildtype MC1R (MC1R-wt). We demonstrate that agouti signalling protein (ASIP) is an 
inverse agonist to the MC1R-wt but is an agonist to the MC1RΔ24. We conclude that the 
eight amino acid deletion of the MC1RΔ24 leads to a constitutively active receptor which is 
further activated by ASIP. This is the first report of ASIP acting as an agonist to MC1R.
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Abbreviations
MC1R:  melanocortin-1receptor
MC1R-wt: melanocortin-1 receptor of the wildtype
MC1RΔ24:  mutant melanocortin-1receptor with 24 base pair deletion
ASIP: agouti signalling protein
POMC: pro-opiomelanocortin
CREB: cAMP responsive element binding protein
TRP-1: tyrosinase-related protein
DCT: dopachrome tautomerase
α-MSH: alpha melanocyte stimulating hormone
cAMP: cyclic adenosine monophosphate
TM: transmembrane helix
ECL: extracellular loop
Introduction
Animal pigmentation is often dramatic and strikingly beautiful and has many 
functions including thermoregulation, crypsis, protection and signalling.1,2,3,4,5,6,7
Colouration is determined by the type, amount and distribution of melanin pigments, 
which are produced in melanocytes found in hair follicles of the epidermis. Mammals 
produce two distinct melanins, phaeomelanin which is red/yellow and eumelanin 
which is brown/black.8 The protein products of the extension and agouti loci have 
been identified as key regulators in the production of these two pigments. The 
extension locus encodes the melanocortin-1 receptor (MC1R) and the agouti encodes 
the agouti signalling protein (ASIP).
The MC1R is a seven transmembrane G protein-coupled receptor (GPCR) 
predominantly expressed in melanocytes. This receptor has a high basal level of 
ligand-independent constitutive activity; however the receptor is activated further by 
its agonist α-melanocyte stimulating hormone (α-MSH).9,10,11 α-MSH is a small 
peptide secreted by the pituitary gland where it is cleaved from the precursor, pro-
opiomelanocortin (POMC). α-MSH is also produced by keratinocytes in the 
epidermis.12 Activation of the MC1R leads to raised intracellular levels of cAMP by 
coupling to adenylate cyclase activity. 13,14 High cAMP levels lead to several 
signalling cascades including changes in gene expression via the cAMP responsive 
element binding protein (CREB) family of transcription factors. 15 Intracellular cAMP 
levels are pivotal in determining the switch from eumelanin to phaeomelanin 
production. Basal levels of cAMP from unstimulated receptors are sufficient to 
stimulate the expression of the gene encoding tyrosinase which is the rate limiting 
enzyme required for the production of both eumelanin and phaeomelanin.16 Lower 
levels of cAMP reduce the expression of genes encoding tyrosinase-related protein 1 
(TRP-1) and dopachrome tautomerase (DCT) which are required for eumelanogenesis 
but not phaeomelanogenesis. Raised cAMP levels have other effects on melanocytes 
including increased dendricity and increased proliferation with the overall effect of 
increased eumelanogenesis.17,18,19
ASIP is a 131 residue peptide produced by dermal papillae cells where it acts in a 
paracrine fashion on follicular melanocytes. In humans and mice, ASIP acts as a high 
affinity inverse agonist of the MC1R, inhibiting binding of the agonist α-MSH and 
inactivating the receptor.20,21 Inactivation of the receptor leads to a fall in cAMP levels 
and a switch to phaeomelanogenesis and ultimately, cessation of pigment 
production.22,23 In this way ASIP acts with the MC1R to form a reversible switch 
determining which type of melanin is synthesised. Cyclical “off” and “on” switching 
of MC1R receptor by ASIP is needed to produce hairs with distinctive banding 
patterns found in wildtype agouti mice.
Wildtype agouti mice produce hairs which are black at the tips and base but contain a 
yellow subapical band. This band corresponds to a switch from eumelanin to 
phaeomelanin synthesis which is caused by a pulse of ASIP expression in the hair 
follicle during day four to six of the hair growth cycle.20 When this transient ASIP 
expression stops, eumelanogenesis resumes. The wildtype grey squirrel (Sciurus  
carolinensis) also produces banded hairs, having a white tip, a band of black and then 
an orange base.24 Melanism in the grey squirrel is associated with an eight amino acid 
deletion in the MC1R.24 The grey phenotype is homozygous for the wildtype MC1R-
wt E+ allele and the jet black phenotype is homozygous for the MC1R∆24 EB allele. 
Jet black squirrels have no agouti banding and produce only solid black hairs 
(supplementary material S1).  
In this study we report how the MC1R of wildtype and melanic squirrels respond to α-
MSH and ASIP in transfected cell models. The results demonstrate that the eight 
amino acid deletion in the MC1R of the melanic grey squirrel leads to a constitutively 
active receptor. We also demonstrate that ASIP acts as an agonist instead of an 
inverse agonist to the MC1RΔ24 melanic variant and offer a working hypothesis as to 
how structural changes caused by this deletion may lead to the observed changes in 
activity. 
Materials and Methods
DNA constructs
Genomic DNA was extracted from muscle tissue of wildtype and jet black squirrels 
using a Qiagen blood and tissue kit following the manufacturer’s instructions. The 
entire coding sequences of the wildtype MC1R-wt E+ (accession number 
EU604831.2) and mutant MC1RΔ24 EB (accession number EU604830.3) genes were 
amplified by PCR in a total volume of 25 µl using approximately 25 ng 
template DNA, 3 mM MgCl2, 0.2 mM dNTPs, 0.4 µM primers, and 0.1 
µl Taq polymerase using the following PCR parameters: initial 
denaturation 94oC for 2 min followed by 35 cycles of 94oC for 30 s, 
68oC  for 30 s, and 72oC  for 5 min. The final extension step was 
performed at 72oC for 30 min. The following primers were used 
(start codon underlined and stop codon removed in the position 
indicated by the vertical line) MC1Rexpf1 5’-
CACCATGGCTGTACAGAGGAGGCTCC -3’, MC1Rexpr1 5’- 
C│CCAGGAGCACAGCAGCACCTCC-3’. PCR products were cloned into a 
pcDNA3.1/CT-GFP-TOPO® Invitrogen expression vector such that the genes were 
tagged with GFP on the C terminus. Constructs were verified by complete 
sequencing. 
Cell culture and transfection
HEK293T cells were routinely maintained in DMEM Glutamax (Invitrogen) 
supplemented with 10% fetal bovine serum and 100U/ml of penicillin and 100 µg/ml 
streptomycin sulphate in 5% CO2 at 37oC. Cells were seeded at 1 ×105 cells/ml into 
24 well plates, in the absence of antibiotic and grown for 24 hours until they were 
80% confluent. Cells were then transiently transfected with expression vectors at 
1µg/µl using Fugene (Promega) following the manufacturer’s instructions with 0.5 µg 
DNA, 1.5 µl Fugene in 25µl opti-MEM® per well.  Confocal visualisation and FACS 
confirmed transfection and protein expression 24 hours after transfection.
Functional assays
All experiments were carried out in triplicate and independent experiments were 
repeated three times. Media were removed from the wells and cells were washed with 
PBS. Varying concentrations of α-MSH (Sigma) and ASIP (93-132-amide mouse, 
Phoenix peptides) were prepared in serum-free media. 400µl of serum-free media 
containing the relevant concentrations of α-MSH and/or ASIP were added to each 
well and cells were incubated at 37oC for 45 minutes. Media were then removed and 
cells were washed carefully with PBS. Ice cold lysis buffer (200μl) was added to each 
well and the cells were shaken in plates for 20 minutes on ice. The contents of each 
well were spun at 13 000 rpm for 10 minutes and cAMP was measured using a 
colorimetric ELISA from Cell Biolabs Inc. following the manufacturer’s instructions. 
Results were normalised against total cellular protein content.
Computer modelling
Computer modelling of the MC1R variants was carried out using Phyre2 and 
Wincoot.25,26 Docking of the MC1R receptor and ASIP used the Fast-Fourier shape 
and electrostatic method of Hex 6.3 followed by side-chain energy minimization and 
clustering of resulting complexes.27 Structural diagrams were prepared using Molsoft 
ICM browser (http://www.molsoft.com).
Results 
Cells transfected with the MC1R-wt gene showed a basal level of activity producing 
10% maximal cAMP (100% maximal response being the production of 0.95 pmole 
cAMP per μg protein in these experiments). The MC1R-wt cells showed a dose 
response to increasing concentrations of α-MSH. With increasing concentrations of α-
MSH, in the presence of 10 μM ASIP, the MC1R-wt cells showed a decrease in 
cAMP production even with the highest concentration of α-MSH at 100 μM (Fig. 
1A). MC1R-wt cells showed a dose response to rising concentration of ASIP with 
decreasing levels of cAMP production (Fig. 1B). In contrast, the MC1RΔ24 
transfected cells showed an elevated level of basal activity (30% maximal), together 
with a dose response to α-MSH. The MC1RΔ24 cells showed an increased level of 
cAMP on stimulation with 10 μM ASIP (70% maximal) and cAMP production 
continued to rise with increasing levels of α-MSH to the maximal response of 100% 
with cells producing  0.95 pmole cAMP per μg protein (Fig. 1A). Contrary to 
expectations, MC1RΔ24 cells showed a dose response to increasing concentrations of 
ASIP with increasing cAMP production (Fig. 1B). These results show that α-MSH is 
an agonist for both MC1R variants but that ASIP, whilst being an inverse agonist for 
MC1R-wt, is actually an agonist for MC1RΔ24. Furthermore, these results show that 
the MC1RΔ24 is constitutively active.
Discussion
During basal activity, GPCRs are in equilibrium between R (inactive) and R* (active) 
states. Agonists bind to the receptor and stabilise the R* conformation leading to full 
activation of a signalling pathway whereas inverse agonists bind to the receptor and 
stabilise the R conformation which leads to a decrease in basal activity. Interestingly, 
it has been shown that inverse agonists are more stabilising whereas agonists induce 
more flexibility.28 In constitutively active receptors, the equilibrium between R and 
R* is moved so that receptors are more often in the R* state.29,30,31,32,33 Many mutations 
leading to constitutive activity disrupt non-covalent intramolecular interactions, 
altering the conformation and local dynamics and binding characteristics of ligand-
binding pockets, and areas distal to such sites. It also seems likely that some 
mutations leading to constitutive activation mimic the active conformation stabilised 
by agonists of the wildtype receptor. However, it is also likely that there is more than 
one conformation that can activate a G protein. The receptor may have a new and 
completely different active conformation that binds to the intracellular effector in a 
different and possibly more effective way. 34,35
MC1Rs have a ligand binding pocket located below the plasma membrane to which 
several transmembrane helices (TMs) contribute.36 There are three residues in 
particular, located deep in the pocket, which are important for ligand binding and 
which are highly conserved in all melanocortin receptors. These residues are E92, 
D117 and D121 (mouse numbering) and they contribute to a highly charged, acidic 
region involved in ligand binding.  The MC1R agonist α-MSH contains the highly 
conserved HFRW sequence. Truncation and mutational studies have shown this to be 
the minimal sequence required for binding and activation of the MC1R.36 The His 
residue of this motif seems to be important for stabilising the ligand-receptor complex 
and its ring formation permits conformational change to take place which is required 
for signal transduction. The neighbouring Phe residue also contributes to a stable 
complex through a hydrophobic aromatic network at the ligand and receptor interface. 
The Arg residue is essential for activation and it is postulated that it interacts with 
E92, D117 and D121 acidic cluster on the receptor. The Arg also seems to be 
important for molecular recognition. 37,38
Analysis of GPCR structures indicate that TM3 acts as an important structural and 
functional 'hub' through contact with four other helices. 34,35 During activation, agonist 
binding generally induces a 2 Å shift of TM3 towards the extracellular side of the 
receptor. This movement alters the position of the highly conserved DRY motif of 
TM3 which, after activation, interacts with the heterotrimeric G protein subunit on the 
cytosolic side of the receptor.39,40 It is predicted that ligand binding provokes this 
movement of TM3 and it is likely that any mutations which alter its interactions are 
likely to affect activity.
A number of mutations on the MC1R are associated with melanism, for example the 
E92K mutation found in mice, chicken, Japanese quail and the bananaquit.41,42,43,44 In 
both the mouse and chicken, this mutation is known to lead to a constitutively active 
receptor.41,45 Mutagenesis studies on the E92 position confirm that a change from an 
acidic to a basic amino acid, either Lys or Arg, leads to constitutive activity. Binding 
studies showed however that the E92K reduced ligand binding.21 It therefore seems 
likely that E92, D115 and D119 are in close proximity, but that they contribute to 
electrostatic repulsion between TM2 and TM3 (Fig. 2 and 3D and E).  The 
introduction of a basic residue could reduce this repulsion and so alter the overall 
structure of the receptor, which might then lead to activation.  Similarly, the C125R 
mutation associated with constitutive activation and melanism in the fox would 
introduce a positive charge and is likely to have a similar agonist mimicking effect.46 
The L98P and L99P mutations associated with constitutive activity and melanism in 
mice and pigs, which introduce a Pro, would likely modify the TM positions and 
again the effect would be transmitted along the TM3.41,47 Thus, it seems likely that the 
effect of the E92K, C125R, L98P and L99P mutations are mimicking the action of the 
Arg residue of α-MSH.21 Studies on the E92K mutation showed that the active 
conformation induced by ligand binding is distinct from that induced by the mutation 
and that the extracellular loop one (ECL1) was involved with maintaining the active 
conformation.48  The effects of these mutations may transmit a conformational change 
along the TM2/TM3 bundle and ultimately can be envisaged to transmit a structural 
signal to the intracellular side of the receptor and in this way affect G protein 
specificity, turnover and/or binding energies. 21
MC1Rs are unusual in having both endogenous agonist and inverse agonists.  ASIP, 
which normally functions as an inverse agonist, is much larger and structurally very 
different to α-MSH. Three functional domains have been identified in ASIP: the C-
terminal loop, the active loop and the N-terminal loop. The active loop contains the 
highly conserved RFF motif which is essential in recognition, binding and inverse 
agonist function and makes direct contact with the receptor in the transmembrane 
pocket.49,50,51 The site of contact is thought to be partially overlapping the site for α-
MSH.52,53 The action of RFF is thought to mimic the action of the HFRW sequence of 
α-MSH. Interestingly, the partial sequence of ASIP, CRFFNAFC, functions not as an 
inverse agonist, but as an agonist.54 Similar short peptides are also agonists to 
MC4R.55 All three loops of ASIP are required for full function as an inverse agonist, 
but studies have shown that chimeras lacking the C-terminal loop have reduced 
binding affinities and most remarkably functioned as agonists.56 This suggests that the 
C-terminal loop is essential for function as an inverse agonist. It has been shown that 
the C-terminal loop forms a contact point with ECL1 of the MC1R (Fig. 3). 
Specifically, the LVARAA sequence of human MC1R and VLSLN of ASIP form 
hydrophobic interactions.56  It has been suggested that with no stabilisation from 
interactions of the C-terminal loop, the RFF active domain relocates to the same 
position as the HFRW motif and thus activates the receptor in a similar way to α-
MSH.52 This relocation may be occurring on the MC1RΔ24 as depicted in figure 4. 
Computer modelling by Phyre2 matches the squirrel MC1R sequence to the adenosine 
a2a receptor (PDB id: 3EML) with 85% coverage and produces a structural model at 
high confidence level. This model predicts that the SNALETTI sequence in the 
MC1R-wt is in TM2 and predicts that deletion of SNALETTI from MC1RΔ24 causes 
the FLLLEVGALA sequence from wildtype ECL1 to be incorporated into TM2 
leading to a truncated ECL1 in the mutant (Fig. 2). Given the finding that ECL1 is 
vital for the ASIP to act as an inverse agonist and that ASIP with no C-terminus loop 
acts as an agonist, it seems likely that the shorter ECL1 of MC1RΔ24 is preventing 
ASIP from inactivating the receptor and instead the ASIP is able to bind to the same 
region as the α-MSH and activate the receptor (Figs. 3 and 4). Interestingly, the 
melanic jaguar and melanic jaguarundis both have deletions in this region of the 
MC1R (Table 1).57 Although these deletions fall in slightly different regions, 
computer models predict that the effects on ECL1 are similar (Fig. 5). Indeed in all 
three species, ECL1 contains a section of β-strand and hydrophobic residues 
important for inverse agonist activity in the wildtype. Figure 5 shows clearly that all 
ECL1s are shortened in the melanic phenotypes with no β-strand and fewer 
hydrophobic residues. It seems likely that these deletions are having similar effects to 
those found in the squirrel, causing changes to agonist and inverse agonist activity and 
causing constitutively active receptors. 
There are a number of ways the eight amino acids deleted in the MC1RΔ24 could be 
altering the function of the receptor. Firstly, the wildtype and mutant TM2s now differ 
substantially and it seems likely that there will be different packing of TM2 and TM3 
between the two cases. It may be hypothesised that TM2 differences and ECL1 
shortening could lead to an upward shift of the TM2-TM3 bundle towards the 
extracellular side thus mimicking the effect of agonist binding, creating the upward 
movement observed in active receptors. Secondly, the E91 of the squirrel MC1R-wt 
(E92 equivalent) is deleted which may, as previously noted, be involved in repulsion 
between TM2 and TM3 in the wildtype. With this repulsion removed, TM2 and TM3 
could be more closely associated. Interestingly, however, models predict an E in 
position 91 in both cases where E99 is relocated into the pocket in the MC1RΔ24 
(Fig. 2 and 3D and E). This replacement could account for the MC1RΔ24 still being 
responsive to α-MSH. It is likely that the E91 will be differently positioned in each 
case which could alter basal activity and could also contribute to an altered interaction 
with ASIP.  Thirdly, with fewer amino acids to contribute to stability and an altered 
arrangement, the MC1RΔ24 receptor may be more flexible than its wildtype 
counterpart and more likely to be in the R* state. Indeed, models predict that N88 of 
SNALETTI forms a hydrogen bond with S124 which is absent in MC1RΔ24.  This 
would be consistent with the finding that the MC1RΔ24 is constitutively active but 
also still responsive to ligands, possibly interacting normally with the remaining 
unaffected loops.  Fourthly, the deleted amino acids may have the opposite effect, 
creating a more stable receptor with an altered architecture and a permanently 
enlarged binding region for the G protein so that it is more often in the R* state. 
These experiments in transfected cells with ASIP [93-132] show that the MC1R-wt 
behaves as a carefully balanced switch capable of activation by α-MSH and 
inactivation by ASIP. In contrast, the MC1RΔ24 has lost the ability to act as an 
effective switch and is constantly activated, having no “off switch”. These results 
suggest that the MC1Rs of the melanic and wildtype squirrel may behave in the same 
way in vivo. In native tissue however, there may be differences in G protein to 
receptor coupling, squirrel ASIP may behave differently to ASIP [93-132] and the 
presence of endogenous α-MSH should be considered. These results predict that the 
MC1R-wt in melanocytes would respond to α-MSH and ASIP producing varying 
levels of intracellular cAMP, ultimately leading to the production of banded 
phaeomelanin/eumelanin hairs of the wildtype grey squirrel. In contrast, melanocytes 
with MC1RΔ24 may only be capable of producing eumelanin leading to the 
production of unbanded jet black hairs of the melanic grey squirrel. Further studies on 
squirrel melanocytes and in vivo studies would be needed to confirm these 
predictions.
 
We conclude that the eight amino acid deletion of the MC1RΔ24 leads to a 
constitutively active receptor, producing a higher basal level of intracellular cAMP 
compared to the MC1R-wt and that ASIP acts as an inverse agonist to MC1R-wt but 
as agonist to MC1R24. This study is the first to date to report that ASIP acts as an 
agonist to the MC1R in any species. 
Figure 1  Functional coupling of MC1R-wt and MC1RΔ24 with α-MSH and ASIP. (A) Changes 
to intracellular levels of cAMP in response to α-MSH in MC1R-wt and MC1RΔ24 transfected 
into HEK293T cells with and without 10,000nM ASIP. (B) Changes to intracellular levels of 
cAMP in response to ASIP in MC1R-wt and MC1RΔ24. Values on the y axis represent basal 
levels of activity in the absence of ligand. Data points show means of triplicates of typical dose 
response curve determination experiments. Error bars indicate standard error of the mean.
AB
Figure 2 Schematic representations of MC1R-wt and MC1RΔ24 based on Phyre2 and Hex6.12 
computer programmes. Amino acid residues that form β-strands are shown as light grey circles. 
(A) Predicted structure of the MC1R-wt showing the eight amino acids (SNALETTI) deleted in 
the MC1RΔ24 as dark grey circles with white lettering. E91, D124 and D128, thought to be 
important in ligand binding are highlighted with bold outline. The highly conserved DRY motif 
of TM3 is shown as black circles with white lettering. (B) Predicted structure of the MC1RΔ24 
showing a shortened extracellular loop 1 (ECL1) compared with the wildtype receptor. The E91 
highlighted with bold outline is the E99 of the wildtype relocated to the helix.
         
 

Figure 3 Computer models of MC1R-wt and MC1RΔ24. (A) Side view of the MC1R-wt and 
MC1RΔ24. (B) MC1R-wt and MC1RΔ24 superimposed on each other. (C) Extracellular view of 
the predicted binding pocket showing TMs. (D) Extracellular view of the predicted binding 
pockets with E91, D114, D118 and melanic equivalents highlighted. (E) Extracellular view of 
binding pockets with Connolly surface shown. (F and G) MC1R-wt and MC1RΔ24 with ASIP, 
showing ASIP C-terminal loop and MC1R ECL1. G also shows the RFF motif in the active loop 
of ASIP as wire representation.
A                                                    B
Figure 4 Schematic representation of ASIP-MC1R-wt and ASIP-MC1RΔ24 interactions. C= C-
terminal loop, A=Active loop and N= N-terminal loop of ASIP. (A) Predicted hydrophobic 
interactions between the C-terminal loop of ASIP and ECL1 of MC1R-wt are shown as black 
circles. (B) Predicted relocation of ASIP when interacting with MC1RΔ24 leading to activation of 
the receptor adapted from Patel et al (2010). 
Figure 5 Schematic representation of TM2, TM3 and ECL1 from the MC1R of wildtype and 
melanic squirrel, jaguar and jaguarundis. Amino acids that form part of β-pleated sheets are 
shown as grey circles. Hydrophobic amino acids are shown as circles with black outlines. 
 
Supplementary material S1 (A) Wildtype S. carolinensis showing banded hairs in the inset. (B) 
Jet black S. carolinensis.
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